Skip to main content
SpringerLink
Log in

In Vivo Models of AI Resistance

  • Chapter
  • First Online:
Resistance to Aromatase Inhibitors in Breast Cancer

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics ((RTACT,volume 8))

  • 590 Accesses

Abstract

The goal of endocrine therapy is to deprive the breast tumor of estrogens, which are key to the growth and progression of the tumor. This can be accomplished by blocking the receptor action via antiestrogens or blocking the biosynthesis of estrogen using aromatase inhibitors. Model systems have been devised to study the effectiveness of hormonal therapy on breast tumor growth. These models proved essential in bringing endocrine agents to the forefront of breast cancer therapy. Now, these models are being exploited to develop strategies to overcome resistance to endocrine agents. Cell lines or tumor xenografts that are deprived of estrogen or treated extensively with aromatase inhibitors serve as models of breast cancers of patients that are receiving AIs in the clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

Δ4A:

Androstenedione

AE:

Antiestrogen

AEs:

Antiestrogens

AIs:

Aromatase inhibitors

Ans:

Anastrozole

E2 :

Estradiol

ER:

Estrogen receptor

Exm:

Exemestane

Let:

Letrozole

Tam:

Tamoxifen

References

  1. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, Group AT. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–9.

    Article  CAS  PubMed  Google Scholar 

  2. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res. 2007;13(23):7029–36.

    Article  CAS  PubMed  Google Scholar 

  3. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions a the new method of treatment, with illustrative cases. The Lancet. 1896;148(3802):104–7.

    Article  Google Scholar 

  4. Belosay A, Brodie AM, Njar VC. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Cancer Res. 2006;66(23):11485–93.

    Article  CAS  PubMed  Google Scholar 

  5. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24(2):85–95.

    Article  CAS  PubMed  Google Scholar 

  6. Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia. 2009;14(1):67–78.

    Article  PubMed  Google Scholar 

  7. Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O. Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol. 2005;95(1–5):41–8.

    Article  CAS  PubMed  Google Scholar 

  8. Brodie A, Lu Q, Liu Y, Long B. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer. 1999;6(2):205–10.

    Article  CAS  PubMed  Google Scholar 

  9. Brodie A, Sabnis G, Macedo L. Xenograft models for aromatase inhibitor studies. J Steroid Biochem Mol Biol. 2007;106(1–5):119–24.

    Article  CAS  PubMed  Google Scholar 

  10. Brodie AM, Garrett WM, Hendrickson JR, Tsai-Morris CH. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model. Cancer Res. 1982;42(8 Suppl):3360s–4s.

    CAS  PubMed  Google Scholar 

  11. Brodie AM, Schwarzel WC, Brodie HJ. Studies on the mechanism of estrogen biosynthesis in the rat ovary–I. J Steroid Biochem. 1976;7(10):787–93.

    Article  CAS  PubMed  Google Scholar 

  12. Brodie AM, Schwarzel WC, Shaikh AA, Brodie HJ. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology. 1977;100(6):1684–95.

    Article  CAS  PubMed  Google Scholar 

  13. Brodie HJ, Kripalani KJ, Possanza G. Studies on the mechanism of estrogen biosynthesis. VI. The stereochemistry of hydrogen elimination at C-2 during aromatization. J Am Chem Soc. 1969;91(5):1241–2.

    Article  PubMed  Google Scholar 

  14. Brooks SC, Locke ER, Soule HD. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J Biol Chem. 1973;248(17):6251–3.

    CAS  PubMed  Google Scholar 

  15. Brown M, Bauer K, Pare M. Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004. Breast Cancer Res Treat. 2010;120(1):217–27.

    Article  PubMed  Google Scholar 

  16. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 1999;140(1–2):27–35.

    Article  CAS  PubMed  Google Scholar 

  17. Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Clin Breast Cancer. 2003;4(Suppl 1):S42–8.

    Article  CAS  PubMed  Google Scholar 

  18. Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol. 2002;81(4–5):333–41.

    Article  CAS  PubMed  Google Scholar 

  19. Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012;134(2):583–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486–92.

    Article  CAS  PubMed  Google Scholar 

  21. Colleoni M, Giobbie-Hurder A, Regan MM, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Lang I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011;29(9):1117–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984;2(8414):1237–9.

    Article  CAS  PubMed  Google Scholar 

  23. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006;66(7):3903–11.

    Article  CAS  PubMed  Google Scholar 

  24. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008;68(18):7493–501.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, investigators AL. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41.

    Article  CAS  PubMed  Google Scholar 

  26. Dowsett M, Coombes RC. Second generation aromatase inhibitor–4-hydroxyandrostenedione. Breast Cancer Res Treat. 1994;30(1):81–7.

    Article  CAS  PubMed  Google Scholar 

  27. Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci USA. 1990;87(17):6698–702.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Geyer RP, Bleisch VR, Bryant JE, Robbins AN, Saslaw IM, Stare FJ. Tumor production in rats injected intravenously with oil emulsions containing 9,10-dimethyl-1,2-benzanthracene. Cancer Res. 1951;11(6):474–8.

    CAS  PubMed  Google Scholar 

  29. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793–802.

    Article  CAS  PubMed  Google Scholar 

  30. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.

    Article  CAS  PubMed  Google Scholar 

  31. Gullino PM, Pettigrew HM, Grantham FH. N-nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst. 1975;54(2):401–14.

    CAS  PubMed  Google Scholar 

  32. Hausler A, Schenkel L, Krahenbuhl C, Monnet G, Bhatnagar AS. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors. J Steroid Biochem. 1989;33(1):125–31.

    Article  CAS  PubMed  Google Scholar 

  33. Huggins CB. Selective induction of hormone-dependent mammary adenocarcinoma in the rat. J Lab Clin Med. 1987;109(3):262–6.

    CAS  PubMed  Google Scholar 

  34. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res. 2005;65(12):5439–44.

    Article  CAS  PubMed  Google Scholar 

  35. Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN, Brodie AM. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res. 2004;10(21):7375–81.

    Article  CAS  PubMed  Google Scholar 

  36. Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 2005;65(12):5380–9.

    Article  CAS  PubMed  Google Scholar 

  37. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O’Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.

    Article  CAS  PubMed  Google Scholar 

  38. Jordan VC. Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J Lab Clin Med. 1987;109(3):267–77.

    CAS  PubMed  Google Scholar 

  39. Kitawaki J, Kim T, Kanno H, Noguchi T, Yamamoto T, Okada H. Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening. J Steroid Biochem Mol Biol. 1993;44(4–6):667–70.

    Article  CAS  PubMed  Google Scholar 

  40. Landis MD, Lehmann BD, Pietenpol JA, Chang JC. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res. 2013;15(1):201.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Leung CK, Shiu RP. Required presence of both estrogen and pituitary factors for the growth of human breast cancer cells in athymic nude mice. Cancer Res. 1981;41(2):546–51.

    CAS  PubMed  Google Scholar 

  42. Long BJ, Jelovac D, Thiantanawat A, Brodie AM. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res. 2002;8(7):2378–88.

    CAS  PubMed  Google Scholar 

  43. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst. 2004;96(6):456–65.

    Article  CAS  PubMed  Google Scholar 

  44. Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 2008;68(9):3516–22.

    Article  CAS  PubMed  Google Scholar 

  45. Martelotto L, Ng C, Piscuoglio S, Weigelt B, Reis-Filho J. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014;16(3):210.

    Article  PubMed Central  Google Scholar 

  46. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003;278(33):30458–68.

    Article  CAS  PubMed  Google Scholar 

  47. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995;80(10):2918–25.

    CAS  PubMed  Google Scholar 

  48. Masri S, Phung S, Wang X, Chen S. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. J Steroid Biochem Mol Biol. 2010;118(4–5):277–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res. 2008;68(12):4910–8.

    Article  CAS  PubMed  Google Scholar 

  50. Mattern J, Bak M, Hahn EW, Volm M. Human tumor xenografts as model for drug testing. Cancer Metastasis Rev. 1988;7(3):263–84.

    Article  CAS  PubMed  Google Scholar 

  51. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367(5):435–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Ng CK, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 2012;12(8):1021–32.

    Article  CAS  PubMed  Google Scholar 

  53. Noel A, Simon N, Raus J, Foidart JM. Basement membrane components (matrigel) promote the tumorigenicity of human breast adenocarcinoma MCF7 cells and provide an in vivo model to assess the responsiveness of cells to estrogen. Biochem Pharmacol. 1992;43(6):1263–7.

    Article  CAS  PubMed  Google Scholar 

  54. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol. 2001;15(8):1344–59.

    CAS  PubMed  Google Scholar 

  55. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985;45(2):584–90.

    CAS  PubMed  Google Scholar 

  56. Ozzello L, Sordat M. Behavior of tumors produced by transplantation of human mammary cell lines in athymic nude mice. Eur J Cancer. 1980;16(4):553–9.

    Article  CAS  PubMed  Google Scholar 

  57. Rebar RW, Morandini IC, Erickson GF, Petze JE. The hormonal basis of reproductive defects in athymic mice: diminished gonadotropin concentrations in prepubertal females. Endocrinology. 1981;108(1):120–6.

    Article  CAS  PubMed  Google Scholar 

  58. Regan MM, Price KN, Giobbie-Hurder A, Thurlimann B, Gelber RD, International Breast Cancer Study and B. I. G. C. Group. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 2011;13(3):209.

    Google Scholar 

  59. Ropero S, Menendez JA, Vazquez-Martin A, Montero S, Cortes-Funes H, Colomer R. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat. 2004;86(2):125–37.

    Article  CAS  PubMed  Google Scholar 

  60. Ryan KJ. Biological aromatization of steroids. J Biol Chem. 1959;234(2):268–72.

    CAS  PubMed  Google Scholar 

  61. Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to “Nude” mice. Acta Pathol Microbiol Scand. 1969;77(4):758–60.

    Article  CAS  PubMed  Google Scholar 

  62. Sabnis G, Brodie A. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Clin Breast Cancer. 2010;10(1):E6–15.

    Article  PubMed  Google Scholar 

  63. Sabnis G, Goloubeva O, Gilani R, Macedo L, Brodie A. Sensitivity to the aromatase inhibitor letrozole is prolonged after a “break” in treatment. Mol Cancer Ther. 2010;9(1):46–56.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res. 2007;13(9):2751–7.

    Article  CAS  PubMed  Google Scholar 

  65. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res. 2009;69(4):1416–28.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol Cancer Ther. 2013;12(12):2804–16.

    Article  CAS  PubMed  Google Scholar 

  67. Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 2005;65(9):3903–10.

    Article  CAS  PubMed  Google Scholar 

  68. Sabnis GJ, Kazi A, Golubeva O, Shah P, Brodie A. Effect of selumetinib on the growth of anastrozole-resistant tumors. Breast Cancer Res Treat. 2013;138(3):699–708.

    Article  CAS  PubMed  Google Scholar 

  69. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J Jr, Berstein L, Yue W. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer. 2005;12(Suppl 1):S61–73.

    Article  CAS  PubMed  Google Scholar 

  70. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Lawrence J Jr, MacMahon LP, Yue W, Berstein L. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol. 2005;95(1–5):155–65.

    Article  CAS  PubMed  Google Scholar 

  71. Shafie SM, Grantham FH. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst. 1981;67(1):51–6.

    CAS  PubMed  Google Scholar 

  72. Shafie SM, Liotta LA. Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Lett. 1980;11(2):81–7.

    Article  CAS  PubMed  Google Scholar 

  73. Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology. 2000;141(1):396–405.

    CAS  PubMed  Google Scholar 

  74. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20(9):1499–504.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51(5):1409–16.

    CAS  PubMed  Google Scholar 

  76. Swain SM. Aromatase inhibitors—a triumph of translational oncology. N Engl J Med. 2005;353(26):2807–9.

    Article  CAS  PubMed  Google Scholar 

  77. Yue W, Brodie A. MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol. 1993;44(4–6):671–3.

    Article  CAS  PubMed  Google Scholar 

  78. Yue W, Zhou D, Chen S, Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 1994;54(19):5092–5.

    CAS  PubMed  Google Scholar 

  79. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 1990;50(21):6949–54.

    CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

There are no potential conflicts of interests.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Experimental Therapeutics, School of Medicine, Health Science Facility I, University of Maryland, Room 580G, 685 W. Baltimore St, Baltimore, MD, 21201, USA

    Gauri Sabnis & Angela Brodie

  2. University of Maryland Greenebaum Cancer Center, Baltimore, MD, 21201, USA

    Angela Brodie

Authors
  1. Gauri Sabnis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela Brodie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela Brodie .

Editor information

Editors and Affiliations

  1. Academic Laboratory of Medical Genetics, School of Clinical Medicine, Cancer Research UK Cambridge Institute, Statistics and Computational Biology Laboratory & University of Cambridge, Cambridge, United Kingdom

    Alexey Larionov

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sabnis, G., Brodie, A. (2015). In Vivo Models of AI Resistance. In: Larionov, A. (eds) Resistance to Aromatase Inhibitors in Breast Cancer. Resistance to Targeted Anti-Cancer Therapeutics, vol 8. Springer, Cham. https://doi.org/10.1007/978-3-319-17972-8_4

Download citation

Publish with us

Policies and ethics

Search

Navigation